Symbols / ENTA Stock $13.31 -0.30% Enanta Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
ENTA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jay R. Luly Ph.D.
Exch · Country NMS · United States
Market Cap 386.25M
Enterprise Value 393.58M
Income -71.54M
Sales 66.98M
FCF (ttm) -1.04M
Book/sh 4.36
Cash/sh 6.40
Employees 120
Insider 10d —
IPO Mar 21, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.36
PEG —
P/S 5.77
P/B 3.05
P/C —
EV/EBITDA -5.78
EV/Sales 5.88
Quick Ratio 4.34
Current Ratio 4.44
Debt/Eq 152.60
LT Debt/Eq —
EPS (ttm) -3.21
EPS next Y -2.09
EPS Growth —
Revenue Growth 9.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-02-09
ROA -13.47%
ROE -60.01%
ROIC —
Gross Margin 100.00%
Oper. Margin -60.45%
Profit Margin -106.80%
Shs Outstand 29.02M
Shs Float 20.20M
Insider Own 4.69%
Instit Own 91.39%
Short Float 8.67%
Short Ratio 16.01
Short Interest 2.10M
52W High 17.15
vs 52W High -22.39%
52W Low 4.96
vs 52W Low 168.35%
Beta 1.00
Impl. Vol. 3.13%
Rel Volume 1.01
Avg Volume 162.82K
Volume 164.73K
Target (mean) $19.86
Tgt Median $20.00
Tgt Low $12.00
Tgt High $28.00
# Analysts 7
Recom Strong_buy
Prev Close $13.35
Price $13.31
Change -0.30%
About

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.86
Mean price target
2. Current target
$13.31
Latest analyst target
3. DCF / Fair value
$-0.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.31
Low
$12.00
High
$28.00
Mean
$19.86

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-10 reit HC Wainwright & Co. Buy → Buy $20
2026-01-09 reit HC Wainwright & Co. Buy → Buy $20
2025-11-14 init JP Morgan — → Overweight $17
2025-09-30 main WestPark Capital Buy → Buy $28
2025-09-15 main Evercore ISI Group Outperform → Outperform $12
2025-09-02 init WestPark Capital — → Buy $24
2025-08-12 main JMP Securities Market Outperform → Market Outperform $25
2025-06-03 main JMP Securities Market Outperform → Market Outperform $24
2025-05-14 main JMP Securities Market Outperform → Market Outperform $23
2025-02-11 reit JMP Securities Market Outperform → Market Outperform $21
2025-02-11 reit HC Wainwright & Co. Buy → Buy $18
2024-12-24 main HC Wainwright & Co. Buy → Buy $18
2024-11-26 main Baird Outperform → Outperform $20
2024-11-26 reit JMP Securities Market Outperform → Market Outperform $21
2024-10-10 reit HC Wainwright & Co. Buy → Buy $27
2024-10-09 reit JMP Securities Market Outperform → Market Outperform $22
2024-09-27 reit JMP Securities Market Outperform → Market Outperform $22
2024-08-06 main JP Morgan Underweight → Underweight $10
2024-08-06 reit HC Wainwright & Co. Buy → Buy $27
2024-05-07 main HC Wainwright & Co. Buy → Buy $27
News
RSS: Latest ENTA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-12 LULY JAY R Chief Executive Officer — 20,000 $0.00 $0
2026-02-12 OR YAT SUN Officer — 6,875 $0.00 $0
2026-02-12 KOWALSKY MATTHEW PAUL Officer — 5,493 $0.00 $0
2026-02-12 KIEFFER TARA LYNN Officer — 6,562 $0.00 $0
2026-02-12 LUU BRENDAN Officer — 6,562 $0.00 $0
2026-02-12 ROTTINGHAUS SCOTT T. Officer — 6,875 $0.00 $0
2025-12-05 LULY JAY R Chief Executive Officer — 4,743 $14.23 $67,493
2025-12-05 TROUT HARRY R III Officer — 542 $14.23 $7,713
2025-12-05 OR YAT SUN Officer — 2,390 $14.23 $34,010
2025-12-05 KIEFFER TARA LYNN Officer — 2,106 $14.23 $29,968
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
65.32
-3.42%
67.64
-14.61%
79.20
-8.07%
86.16
Operating Revenue
65.32
-3.42%
67.64
-14.61%
79.20
-8.07%
86.16
Operating Expense
150.67
-20.42%
189.33
-12.52%
216.41
+3.05%
210.00
Research And Development
106.74
-18.81%
131.48
-19.60%
163.52
-0.61%
164.52
Selling General And Administration
43.93
-24.06%
57.85
+9.38%
52.89
+16.28%
45.48
General And Administrative Expense
43.93
-24.06%
57.85
+9.38%
52.89
+16.28%
45.48
Other Gand A
43.93
-24.06%
57.85
+9.38%
52.89
+16.28%
45.48
Total Expenses
150.67
-20.42%
189.33
-12.52%
216.41
+3.05%
210.00
Operating Income
-85.35
+29.86%
-121.69
+11.31%
-137.21
-10.79%
-123.84
Total Operating Income As Reported
-85.35
+29.86%
-121.69
+11.31%
-137.21
-10.79%
-123.84
EBITDA
-71.28
+31.80%
-104.51
+15.36%
-123.48
-3.57%
-119.22
Normalized EBITDA
-71.32
+31.81%
-104.58
+15.30%
-123.48
-3.50%
-119.30
Reconciled Depreciation
4.59
+96.32%
2.34
-1.48%
2.37
-20.25%
2.97
EBIT
-75.87
+28.99%
-106.85
+15.10%
-125.85
-2.99%
-122.19
Total Unusual Items
0.04
-46.58%
0.07
—
0.08
Total Unusual Items Excluding Goodwill
0.04
-46.58%
0.07
—
0.08
Net Income
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Pretax Income
-83.55
+29.07%
-117.79
+10.08%
-131.00
-7.21%
-122.19
Net Non Operating Interest Income Expense
1.76
-54.02%
3.83
-38.35%
6.21
+294.91%
1.57
Interest Expense Non Operating
7.68
-29.79%
10.94
+112.51%
5.15
0.00
Net Interest Income
1.76
-54.02%
3.83
-38.35%
6.21
+294.91%
1.57
Interest Expense
7.68
-29.79%
10.94
+112.51%
5.15
0.00
Interest Income Non Operating
9.44
-36.07%
14.77
+30.02%
11.36
+622.19%
1.57
Interest Income
9.44
-36.07%
14.77
+30.02%
11.36
+622.19%
1.57
Other Income Expense
0.04
-46.58%
0.07
—
0.08
Other Non Operating Income Expenses
—
—
—
0.08
Gain On Sale Of Security
0.04
-46.58%
0.07
—
0.08
Tax Provision
-1.66
+4.76%
-1.74
-161.79%
2.82
+751.50%
-0.43
Tax Rate For Calcs
0.00
+33.33%
0.00
-92.86%
0.00
+5150.00%
0.00
Tax Effect Of Unusual Items
0.00
-28.77%
0.00
0.00
-100.00%
0.00
Net Income Including Noncontrolling Interests
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Net Income From Continuing Operation Net Minority Interest
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Net Income From Continuing And Discontinued Operation
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Net Income Continuous Operations
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Normalized Income
-81.93
+29.44%
-116.12
+13.23%
-133.82
-9.83%
-121.84
Net Income Common Stockholders
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Diluted EPS
-3.84
+29.93%
-5.48
+14.11%
-6.38
-7.95%
-5.91
Basic EPS
-3.84
+29.93%
-5.48
+14.11%
-6.38
-7.95%
-5.91
Basic Average Shares
21.34
+0.85%
21.16
+0.90%
20.97
+1.78%
20.60
Diluted Average Shares
21.34
+0.85%
21.16
+0.90%
20.97
+1.78%
20.60
Diluted NI Availto Com Stockholders
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
280.73
-25.47%
376.65
-18.52%
462.27
+23.14%
375.41
Current Assets
204.34
-31.85%
299.85
-29.08%
422.79
+35.63%
311.71
Cash Cash Equivalents And Short Term Investments
188.86
-23.90%
248.19
-32.91%
369.91
+48.42%
249.23
Cash And Cash Equivalents
32.30
-13.25%
37.23
-56.40%
85.39
+94.09%
43.99
Other Short Term Investments
156.57
-25.78%
210.95
-25.86%
284.52
+38.63%
205.24
Receivables
6.88
-82.19%
38.65
-2.46%
39.62
-19.21%
49.04
Accounts Receivable
6.88
+3.55%
6.65
-22.85%
8.61
-57.60%
20.32
Taxes Receivable
0.00
-100.00%
32.00
+3.21%
31.00
+7.96%
28.72
Prepaid Assets
—
—
—
13.45
Restricted Cash
0.00
-100.00%
0.61
0.00
—
Other Current Assets
8.59
-30.80%
12.41
-6.41%
13.26
-1.35%
13.45
Total Non Current Assets
76.40
-0.53%
76.80
+94.51%
39.48
-38.01%
63.70
Net PPE
72.94
-0.55%
73.35
+111.29%
34.71
+16.69%
29.75
Gross PPE
96.75
-1.67%
98.39
+68.31%
58.46
+13.28%
51.61
Accumulated Depreciation
-23.80
+4.96%
-25.05
-5.48%
-23.75
-8.63%
-21.86
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
21.00
-0.06%
21.01
+2.06%
20.59
+13.12%
18.20
Construction In Progress
0.00
-100.00%
22.75
+1686.96%
1.27
-50.20%
2.56
Other Properties
37.55
-7.65%
40.66
+78.37%
22.79
-3.31%
23.57
Leases
38.20
+173.35%
13.97
+1.24%
13.80
+89.72%
7.28
Investments And Advances
—
—
0.00
-100.00%
29.29
Other Non Current Assets
3.45
-0.06%
3.45
-27.60%
4.77
+2.29%
4.66
Total Liabilities Net Minority Interest
216.01
-12.84%
247.84
+0.94%
245.54
+354.06%
54.08
Current Liabilities
48.55
-15.61%
57.53
-8.36%
62.79
+110.50%
29.83
Payables And Accrued Expenses
14.70
-31.79%
21.55
-3.95%
22.44
-16.71%
26.94
Payables
1.95
-75.66%
8.00
+95.31%
4.10
-31.72%
6.00
Accounts Payable
1.95
-75.66%
8.00
+95.31%
4.10
-31.72%
6.00
Current Accrued Expenses
12.75
-5.88%
13.55
-26.13%
18.34
-12.40%
20.94
Current Debt And Capital Lease Obligation
3.15
+106.43%
1.52
-71.11%
5.28
+82.46%
2.89
Current Capital Lease Obligation
3.15
+106.43%
1.52
-71.11%
5.28
+82.46%
2.89
Other Current Liabilities
30.71
-10.89%
34.46
-1.75%
35.08
—
Total Non Current Liabilities Net Minority Interest
167.46
-12.00%
190.30
+4.13%
182.75
+653.65%
24.25
Long Term Debt And Capital Lease Obligation
54.76
+1.51%
53.94
+153.99%
21.24
-5.07%
22.37
Long Term Capital Lease Obligation
54.76
+1.51%
53.94
+153.99%
21.24
-5.07%
22.37
Other Non Current Liabilities
111.39
-17.49%
135.01
-15.67%
160.09
+35162.56%
0.45
Preferred Securities Outside Stock Equity
1.31
-2.89%
1.35
-5.13%
1.42
+0.00%
1.42
Stockholders Equity
64.72
-49.76%
128.81
-40.57%
216.74
-32.55%
321.33
Common Stock Equity
64.72
-49.76%
128.81
-40.57%
216.74
-32.55%
321.33
Capital Stock
0.21
+0.94%
0.21
+0.47%
0.21
+1.44%
0.21
Common Stock
0.21
+0.94%
0.21
+0.47%
0.21
+1.44%
0.21
Share Issued
21.39
+0.91%
21.19
+0.64%
21.06
+1.29%
20.79
Ordinary Shares Number
21.39
+0.91%
21.19
+0.64%
21.06
+1.29%
20.79
Additional Paid In Capital
469.77
+4.08%
451.34
+6.27%
424.69
+6.70%
398.03
Retained Earnings
-404.93
-25.35%
-323.04
-56.06%
-207.00
-182.86%
-73.18
Gains Losses Not Affecting Retained Earnings
-0.34
-212.25%
0.30
+125.72%
-1.17
+68.47%
-3.72
Other Equity Adjustments
-0.34
-212.25%
0.30
+125.72%
-1.17
+68.47%
-3.72
Total Equity Gross Minority Interest
64.72
-49.76%
128.81
-40.57%
216.74
-32.55%
321.33
Total Capitalization
64.72
-49.76%
128.81
-40.57%
216.74
-32.55%
321.33
Working Capital
155.78
-35.71%
242.32
-32.69%
360.00
+27.71%
281.89
Invested Capital
64.72
-49.76%
128.81
-40.57%
216.74
-32.55%
321.33
Total Debt
57.90
+4.39%
55.47
+109.21%
26.51
+4.95%
25.26
Capital Lease Obligations
57.90
+4.39%
55.47
+109.21%
26.51
+4.95%
25.26
Net Tangible Assets
64.72
-49.76%
128.81
-40.57%
216.74
-32.55%
321.33
Tangible Book Value
64.72
-49.76%
128.81
-40.57%
216.74
-32.55%
321.33
Available For Sale Securities
—
—
—
29.29
Investmentin Financial Assets
—
—
0.00
-100.00%
29.29
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-19.27
+75.53%
-78.76
+23.64%
-103.15
-21.67%
-84.78
Cash Flow From Continuing Operating Activities
-19.27
+75.53%
-78.76
+23.64%
-103.15
-21.67%
-84.78
Net Income From Continuing Operations
-81.89
+29.43%
-116.05
+13.28%
-133.82
-9.91%
-121.75
Depreciation Amortization Depletion
4.59
+96.32%
2.34
-1.48%
2.37
-20.25%
2.97
Depreciation
4.59
—
—
—
Depreciation And Amortization
4.59
+96.32%
2.34
-1.48%
2.37
-20.25%
2.97
Other Non Cash Items
-0.95
-144.44%
2.14
+140.85%
-5.24
-464.37%
-0.93
Stock Based Compensation
18.57
-30.71%
26.80
-5.04%
28.22
+4.62%
26.97
Deferred Tax
—
—
0.00
0.00
Deferred Income Tax
—
—
0.00
0.00
Operating Gains Losses
0.01
-62.50%
0.02
-89.33%
0.15
—
Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
0.01
-62.50%
0.02
-89.33%
0.15
0.00
Change In Working Capital
39.91
+459.73%
7.13
-11.14%
8.02
+18.19%
6.79
Change In Receivables
31.76
+3164.44%
0.97
-89.67%
9.42
-20.15%
11.79
Changes In Account Receivables
-0.24
-111.99%
1.97
-83.19%
11.70
+259.24%
3.26
Change In Prepaid Assets
3.82
+349.76%
0.85
+367.03%
0.18
-75.50%
0.74
Change In Payables And Accrued Expense
-1.25
+79.32%
-6.06
-63.39%
-3.71
+39.31%
-6.11
Change In Accrued Expense
0.06
+101.03%
-5.65
-120.72%
-2.56
-73.19%
-1.48
Change In Payable
-1.31
-216.67%
-0.41
+64.03%
-1.15
+75.16%
-4.63
Change In Account Payable
-1.31
-216.67%
-0.41
+64.03%
-1.15
+75.16%
-4.63
Change In Other Working Capital
—
—
—
-0.60
Change In Other Current Assets
4.31
-36.66%
6.80
+51.53%
4.49
+7.65%
4.17
Change In Other Current Liabilities
1.27
-72.25%
4.56
+293.47%
-2.36
+38.11%
-3.81
Investing Cash Flow
40.35
-30.72%
58.23
+208.69%
-53.58
-197.60%
54.90
Cash Flow From Continuing Investing Activities
40.35
-30.72%
58.23
+208.69%
-53.58
-197.60%
54.90
Net PPE Purchase And Sale
-12.90
+28.15%
-17.95
-98.15%
-9.06
-326.26%
-2.12
Purchase Of PPE
-12.90
+28.15%
-17.95
-98.15%
-9.06
-326.26%
-2.12
Capital Expenditure
-12.90
+28.15%
-17.95
-98.15%
-9.06
-326.26%
-2.12
Net Investment Purchase And Sale
53.24
-30.11%
76.18
+271.12%
-44.52
-178.08%
57.02
Purchase Of Investment
-209.63
+31.78%
-307.28
+17.71%
-373.39
-117.79%
-171.45
Sale Of Investment
262.87
-31.45%
383.46
+16.60%
328.87
+43.95%
228.47
Financing Cash Flow
-26.62
+3.65%
-27.63
-113.94%
198.13
+889.00%
20.03
Cash Flow From Continuing Financing Activities
-26.62
+3.65%
-27.63
-113.94%
198.13
+889.00%
20.03
Net Issuance Payments Of Debt
—
-27.48
0.00
0.00
Repayment Of Debt
—
-27.48
0.00
0.00
Long Term Debt Payments
—
-27.48
0.00
0.00
Net Long Term Debt Issuance
—
-27.48
0.00
0.00
Proceeds From Stock Option Exercised
0.14
-1.36%
0.15
-93.34%
2.21
-89.62%
21.26
Net Other Financing Charges
-26.76
+3.64%
-27.77
-114.18%
195.92
+16041.25%
-1.23
Changes In Cash
-5.54
+88.49%
-48.16
-216.33%
41.39
+520.16%
-9.85
Beginning Cash Position
41.20
-53.89%
89.36
+86.31%
47.96
-17.04%
57.81
End Cash Position
35.66
-13.45%
41.20
-53.89%
89.36
+86.31%
47.96
Free Cash Flow
-32.17
+66.74%
-96.71
+13.81%
-112.21
-29.12%
-86.91
Interest Paid Supplemental Data
8.79
-24.90%
11.71
+489.33%
1.99
0.00
Income Tax Paid Supplemental Data
0.11
-54.77%
0.24
-95.08%
4.90
0.00
Amortization Of Securities
0.50
+144.20%
-1.14
+60.15%
-2.86
-343.89%
1.17
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category